Biogen Inc. will ask U.S. drug regulators to approve the companyâs experimental Alzheimerâs therapy, reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising results.
Fuente: Youtube
Biogen Inc. will ask U.S. drug regulators to approve the companyâs experimental Alzheimerâs therapy, reviving the nearly abandoned treatment after a new analysis of data from two failed clinical trials showed promising results.
Fuente: Youtube